Supernus to Present at Two November Healthcare Conferences
ROCKVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present a Company overview and update, as well as host investor meetings, at the following November conferences:
| Stifel 2019 Healthcare Conference | |
| Date: | November 19, 2019 |
| Time: | 1:50 p.m. ET |
| Place: | Lotte New York Palace Hotel, New York |
| Jefferies 2019 London Healthcare Conference | |
| Date: | November 21, 2019 |
| Time: | 2:40 p.m. GMT / 9:40 a.m. ET |
| Place: | Waldorf Hilton, London, UK |
Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.
A live webcast of the presentations can be accessed by visiting ‘Events & Presentations’ in the Investor Relations section on the Company's website at . An archived replay of these webcasts will be available for 60 days on the Company's website after the respective conferences.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD and SPN-604 for the treatment of bipolar disorder.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke, an ICR Company
Office: (443) 213-0505
Mobile: (443) 377-4767
Email:
